Finerenone Struktur

Finerenone

Bezeichnung:Finerenone

CAS-Nr1050477-31-0

Englisch Name:Finerenone

CBNumberCB72744895

SummenformelC21H22N4O3

Molgewicht378.42

MOL-Datei1050477-31-0.mol

Finerenone physikalisch-chemischer Eigenschaften

Siedepunkt	554.7±50.0 °C(Predicted)
Dichte	1.29±0.1 g/cm3(Predicted)
storage temp.	-20°C
Löslichkeit	DMF: 10 mg/ml DMSO: 3 mg/ml Ethanol: insol PBS (pH 7.2): insol
pka	14.76±0.40(Predicted)
Aggregatzustand	solid
Farbe	White to off-white
maximale Wellenlänge (λmax)	255 nm
InChI	InChI=1S/C21H22N4O3/c1-5-28-21-18-17(14-7-6-13(9-22)8-15(14)27-4)16(20(23)26)12(3)25-19(18)11(2)10-24-21/h6-8,10,17,25H,5H2,1-4H3,(H2,23,26)/t17-/m1/s1
InChIKey	BTBHLEZXCOBLCY-QGZVFWFLSA-N
SMILES	N1C2=C(C(OCC)=NC=C2C)[C@H](C2=CC=C(C#N)C=C2OC)C(C(N)=O)=C1C

Gefahreninformationscode (GHS)

Finerenone Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
Finerenone is a novel mineralocorticoid receptor antagonist that has the effect of delaying the progression of chronic kidney disease. Some people may be aware of two other mineralocorticoid receptor antagonists: the diuretic antihypertensive drug spironolactone, and eplerenone.Finerenone is their cognate derivative and is a third-generation mineralocorticoid receptor antagonist. So far, finerenone is the only nonsteroidal mineralocorticoid receptor antagonist to be FDA approved. Finerenone was granted FDA approval on 9 July 2021, followed by the EMA approval on 11 March 2022.
Verwenden
Finerenone is the first non-steroidal selective mineralocorticoid receptor antagonist, which can be used for the treatment of diabetic nephropathy, chronic kidney disease and end-stage renal disease. It can reduce the proteinuria of patients and improve the glomerular filtration rate.
Trademarks
Finerenone is sold under the brand name Kerendia and Firialta.
Biologische Aktivität
Finerenone (FIN, BAY 94-8862) is a highly selective, orally active, nonsteroidal antagonist of mineralocorticoid receptor (MR) with IC50 of 18 nM. Finerenone has the potential to study cardio-renal diseases such as type 2 diabetes and chronic kidney disease.
in vivo
Finerenone (BAY 94-8862) lowers albuminuria by >40% and significantly reduces systolic blood pressure (SBP) in Munich Wistar Fr?mter (MWF) rat.
Mode of action
Finerenone is a Nonsteroidal Mineralocorticoid-Receptor Antagonist. The mechanism of action of finerenone is as a Mineralocorticoid Receptor Antagonist. Finerenone inhibits the effects of mineralocorticoids like aldosterone and cortisol when the MR is overactivated, possibly reducing inflammation and fibrosis in the heart and kidney.
Einzelnachweise
Kolkhof, P., Hartmann, E., Freyberger, A., et al.Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage. Am. J. Nephrol. 52(8), 642-652 (2021).
DOI: 10.1159/000516213
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.

Finerenone Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Send Inquriy